Dinghang pharmaceutical and mereo reach an exclusive license agreement for global development and commercialization

Dinghang pharma and mereo biopharma announced on January 13 that they had reached a global license agreement on navicizumab ("Navi"), and dinghang Pharma would obtain the exclusive license for global development and commercialization of Navi Navi is an innovative bispecific antibody against Dll4 / VEGF At present, a phase 1b clinical study combined with paclitaxel is being carried out to treat advanced ovarian cancer patients who fail in the early treatment Navi is the main pipeline product when mereo and oncomed pharmaceuticals are merged in 2019 Before that, a Phase-A single drug treatment clinical study for multiple refractory solid tumors has been completed In October 2019, the U.S Food and Drug Administration (FDA) granted Navi fast track certification, and agreed in principle to a clinical study design, which is expected to support accelerated Navi approval in the population of platinum resistant ovarian cancer patients who failed in the early treatment According to the agreement between the two parties, dinghang pharmaceutical will obtain the exclusive authorization of Navi for global development and commercialization, and mereo will receive the advance payment of USD 4 million for this purpose, as well as the additional milestone payment of USD 2 million for CMC (Chemistry, production and control) Dinghang pharmaceutical will be responsible for all future research, development and commercialization activities of Navi In addition, mereo will be eligible for up to $300 million in revenue, including future clinical, registration and commercialization milestones, royalties for global annual net sales, etc "We believe that dinghang pharmaceutical can further develop Navi and eventually commercialize it." Dr Denise Scots knight, CEO of mereo, said, "mereo will focus on the development of innovative product portfolio of drugs for rare diseases, but we always firmly believe Navi is a potential cancer candidate."